170900.KS
Dong-A ST Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 36,900.00
−0.54%Year over year
Reported trailing growth
- Revenue
- +15.4%
- EBITDA
- —
- EBIT
- +286.9%
- EPS
- +63.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +3.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.4%
- EBITDA
- -12.2%
- EBIT
- -66.7%
- Net income
- —
- EPS
- —
- Free cash flow
- +77.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026